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We describe the response of imatinib as lifesaving treatment of chronic myeloid leukemia (CML) relapse in seven patients who
underwent allogeneic bone marrow transplantation (alloBMT) at our institution over a period of 4 years. Retrospective analysis
of their medical records revealed that a mean age at transplant was 45.2 years. The median time to diagnosis was 7.4 years after
transplant. At relapse, four, two, and one patients were classiﬁed as having hematologic, major molecular, and cytogenetic relapse,
respectively. At imatinib initiation, ﬁve had CML in a chronic phase, while one patient was diagnosed as having accelerated phase
and blast crisis. All these patients could be evaluated for the therapeutic eﬃcacy. At a mean of follow-up of 1.9 years of therapy,
all evaluable patients achieved major molecular response without compromising safety. Consistent with available data, our results
indicate that imatinib is safe and eﬀective treatment option for patients with relapse after BMT.
Copyright © 2009 Monika Conchon et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Chronicmyeloidleukemia(CML)isamyeloproliferativedis-
ease that represents 15%–25% of all leukemias. The disease
was the result of a reciprocal translocation between chro-
mosome 22 and chromosome 9, the so-called Philadelphia
translocation [1]. This rearrangement joins the c-ABL gene
on chromosome 9 and BCR on chromosome 22 creating a
BCR-ABL fusion gene, which codes for a 190–230kDa, BCR-
ABLfusionproteinwithelevatedtyrosinekinaseactivity.The
upregulated BCR-ABL fusion protein includes the tyrosine
kinase domain, which likely contributes to dysregulation of
the mechanism of cellular signals transduction, normally
involved in controlling apoptosis, proliferations, and cell-
cell adhesions, and thus promoting leukemogenesis [2]. The
abrogation of BCR-ABL function has become a model for
development of targeted therapies. The enzymatic inhibition
of BCR-ABL using Imatinib mesylate (GleevecTM, STI571;
Novartis Pharmaceutical Corp., East Hanover, NJ) has been
shown to possess potent in vitro and in vivo activities in pre-
clinical studies [3,4].Theactivity ofthis inhibitor in patients
with previously treated CML was further conﬁrmed in early
clinical trials [5–7]. Recently, the landmark International
Randomized Study of Interferon versus STI571 (IRIS) study
has shown cytogenetic responses in 87% of their patients
after 5 years of imatinib as a primary treatment [8]. Over the
past few decades, allogeneic bone marrow transplantation
(allo-BMT) has been used to treat CML and other malignant
and nonmalignant diseases. This therapeutic option brought
a fair amount of success and proved to prolong survival.2 Journal of Transplantation
However, this success is frequently not maintained since
leukemic relapse substantially occurs in 30% to 60% of
patients who undergo transplantation during the advanced
stages of disease (accelerated phase and blast crisis) and 5%
to 20% of those who undergo transplantation during the
chronic phase [7]. Moreover, the impact of this potential
treatment is limited because it depends considerably on the
patient’s age and availability of a genetically cross matching
donor with the same tissue type to prevent rejection [9]. The
infusionofdonorlymphocytes(DLI)intoCMLpatientswho
have relapsed following an allo-BMT has been frequently
u s e da n dp r o v e dt oe ﬀectively treat 70%–80% of patients
with relapsed chronic leukemia. However, this therapeutic
optionislesseﬀectiveinpatientswithmoreadvanceddisease
and may also be associated with severe marrow aplasia, high
incidence of chronic graft-versus-host disease (GVHD), and
transplant-related mortality [10–12]. Several studies have
shown that the administration of imatinib is safe and highly
eﬀective in controlling leukemic relapses after allo-BMT
[13,14].Thesecompellingfactshavemadeusadoptimatinib
therapy as the preferred treatment at our institution. In this
study, we performed a retrospective analysis to determine
the eﬃcacy of imatinib administration in treating leukemic
relapses after allo-BMT.
2.MaterialsandMethods
From January 2005 to January 2009, a total of 7 cases with
primary relapse of CML after allo-BMT undergoing treat-
ment with imatinib were found after a retrospective search
of the CML database at the Department of CML Ambulatory
of the Hospital das Clinicas, S˜ ao Paulo University. Patients’
medical records were reviewed for the following: sex, age,
date of CML diagnosis, time from diagnosis to transplant,
time from transplant to relapse, disease stage at relapse, and
other variables as shown in Table 1. The extent of CML
was staged (chronic, accelerated or blast phase) according
to the 2008 revision of the World Health Organization
staging system. In all patients, complete blood counts were
performed weekly for the ﬁrst month of follow-up and
monthly thereafter. Quantiﬁcation of BCR-ABL transcript
numbers was measured every 3 months by real-time PCR
and conventional bone marrow cytogenetics were performed
every 6 months and then every 12 months.
Response criteria were as previously described [15, 16].
Cytogenetic response was classiﬁed as complete (no Ph
chromosome-positive cells in metaphase in the bone mar-
row), partial (1%–34% Ph chromosome-positive cells), or
minor (35%–90% Ph chromosome-positive cells). Major
cytogenetic responses included complete and partial cyto-
genetic responses [17]. Molecular response was considered
major if the BCR-ABL level was below 0.1% and complete
when it was negative.
Toxicities were assessed according to the National Cancer
Institute Common Toxicity Criteria version 3.0 (National
Cancer Institute, Bethesda, MD). Posttransplant allogeneic
hematopoietic chimerism was evaluated by ﬂuorescent-
based PCR ampliﬁcation and capillary gel electrophoresis
of microsatellite DNA STR markers in sequential peripheral
blood and bone marrow samples from the recipients using
established techniques [18].
Curves of overall survival and progression free survival
were estimated using the Kaplan and Meier method.
3. Results
A total of seven patients were treated with imatinib after hav-
ingundergonealloBMT.Thesubjects’meanageattransplant
was 45.2 years (Table 1). Males contributed to 57.1% of the
sample.All7patientsreceivedanallogeneicperipheralblood
progenitor cell from HLA-identical sibling. The median time
to diagnosis was 7.4 years after transplant. At the time of
relapse, four patients were classiﬁed as having a hematologic
relapse, two as having a major molecular relapse, and one as
having a cytogenetic relapse. The mean time from alloBMT
to detection of relapse was 4.02 years. Two patients received
a DLI as a salvage therapy after relapse to enhance donor
engraftmentwithoutresponse.Ofthesevenpatients,ﬁvehad
CML in a chronic phase at the time of imatinib initiation,
while one patient was diagnosed as having accelerated phase
and blast crisis. Imatinib was given at a dose of 400mg/d
(ﬁve patients) or 600mg/d (two patients). One patient failed
to show any response to treatment. This latter patient was
in blastic crisis before imatinib administration and died
of rapid disease progression 7 months after initiation of
therapy, before hematologic recovery. Eventually, all patients
could be evaluated for the therapeutic eﬃcacy. At a mean of
follow-up of 1.8 years of imatinib therapy, all but one patient
had achieved complete hematologic, cytogenetic, and major
molecular response. The mean time of major molecular
response was 5.6 months. Response to imatinib was then
evaluated based on relapse classiﬁcation and found that all
but one patient with hematologic relapse achieved major
molecular response. Analyses of the safety data in patients
who remained alive indicate that the treatment was generally
well tolerated and that most of toxicities were mild and
transient. Four patients experienced grade 2 hematological
toxicities, while one patient developed grade 2 alterations in
hepatic enzymes. Complete donor chimerism was achieved
after transplantation in all six evaluable patients. The
estimated overall and progression-free survivals were 7.1 and
2.1 years, respectively.
4. Discussion
A number of therapeutic interventions have met with
varying degrees of success in the treatment of CML patients
with relapse after allo-BMT. These options include a second
transplant [19, 20], conventional cytotoxic chemotherapy,
and interferon-alpha [21]. Each treatment, however, has
limitations. For example, although the option of second
allo-BMT oﬀers a prospect of cure, it is limited to young
patients with good performance status and is associated with
av e r yp o o ro u t c o m e[ 10, 21, 22]. Evidence from several
reports indicated a high remission rate (70%–80%) after
DLI in chronic phase CML. However, the success of thisJournal of Transplantation 3
Table 1: Patients characteristics, CML stage and IM response. F: Female, M: Male, Δsis: Diagnosis, CP: chronic phase, BC: blastic crisis, AP:
accelerated phase, IM: imatinib, Mol: molecular, Hem: hematologic, Cyt: cytogenetic, Hep: hepatic, MMR: major molecular reponse, NR:
no reponse.
Case
number
Sex Age
(years)
Δsis 1st line
therapy
Type of relapse
at IM therapy
IM dose
(mg/d)
Maximum
IM reponse
Time to acheive
MMR (month)
Toxicity
Current
RT-PCR
status
1 M 28 CML (CP) IM Mol 400 MMR 3.7 No Negative
2 F 44 CML (CP) IM Cyt 400 MMR 9.2 No Positive
3 M 50 CML (CP) 3X Hem 400 MMR 3 No Negative
4 F 47 CML (CP) 1X Hem 400 MMR 6 Hem Positive
5 M 55 CML (BC) IM Hem 600 NR — Hem —
6 F 48 CML (CP) IM Mol 400 MMR 2 Hep Positive
7 F 45 CML (AP) IM Hem 600 MMR 9.5 Hem Positive
option has been limited by short duration of response,
myelosuppression, signiﬁcant GVHD, and rare long-term
survival [1, 5, 19]. It is therefore important to consider the
eﬀects of the alternative therapies listed above on outcomes.
The recent use of imatinib mesylate as new therapeutic
approach is eventually become accepted as the preferred
treatment of posttransplant relapse setting and oﬀers a num-
ber of potential advantages over DLI including fewer adverse
eﬀects and relatively rapid and durable response. Apart from
our study, several anecdotal and clinical trials have examined
the use of imatinib in patients with relapse after BMT.
The largest of these was a prospective phase II open label
multicenter study by Hess et al. [13] who examined the use
of imatinib therapy in 44 relapsed patients. In this 494-day
median follow-up study, patients were treated with imatinib
at starting dose of 400mg/d and escalated to 600mg/d to
800mg/difpatientsdidnotachieveMMR.Ofthe37patients
assessable for eﬃcacy analysis, a total of 23 patients (62%)
had a CMR during the initial 9 months, which improved to
70% during follow-up. Therapy was generally well tolerated,
with a main adverse event of neutropenia/leucopenia. The
review by Palandri and coworkers [23] of the outcomes of
16 patients who received imatinib as ﬁrst or second line
therapy showed that 93% of this group achieved a molecular
negativity after 3–27 months and 75% had negative reverse
transcriptase-polymerase chain reaction after12–45 months.
Similarly, Hayat et al. [24] found, in a group of 14 patients
who relapsed postallo-BMT from the preimatinib era, that
93% had achieved excellent response to imatinib with a
median time of 4 months.
In this study, although the sample size is small, imatinib
maintained MMR in all 6 evaluable patients for an average
time of 21 months of follow-up. All patients are still on
treatment with imatinib and have full-donor chimerism
according to the last analysis. Generally, the results presented
here compare favorably with the outcomes from previous
studies [13, 19, 25] and lend support to the conclusion that
the imatinib therapy is eﬃciently improving outcome even
further in patients with relapse after BMT particularly for
chronic phase CML without compromising safety.
Although the introduction of imatinib has obviously
been a major step forward a high objective response and
disease stabilization rate in patients with relapse after BMT,
several questions still remain open. Among them, how well
doesimatinibperformoverthelong-termoftherapy?Isthere
a tendency for some patients to gradually relapse overtime
passage? Can patients eventually stop their therapy without
relapsing? To provide answers to these questions, additional
double-blind imatinib-placebo controlled research of long-
term follow-up is needed to further evaluate the safety of a
long-term, continuous therapy with the imatinib in a large
number of patients with relapse after BMT.
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